Article
How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?
13 Jan 2012
Abstract excerpt
Over the last decade, advances in diagnostic systems and the introduction of new antifungal agents have significantly improved outcomes in immunocompromised patients who develop invasive aspergillosis. However, mortality rates remain relatively unchanged for less common, but highly aggressive, mold infections such as mucormycosis. Recent genome sequencing of Rhizopus oryzae revealed evidence of a whole-genome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
